Dr. Trish Hurter is a senior pharmaceutical and bio-tech executive who contributed to four approved breakthrough drugs, and conceived and executed the first FDA-approved continuous manufacturing facility in the world. She has a 25+ year multi-faceted background in drug discovery and development, which she is leveraging in her new role as CEO of Lyndra Therapeutics, Inc. Dr. Hurter was instrumental in the development of several approved, highly successful therapies including Incivek, Kalydeco, Orkambi, Symdeko, and Januvia. Her straightforward approach, analytical drive and boundless problem-solving energy ensure breakthrough therapies reach the market with unprecedented speed.
Dr. Hurter is currently CEO and President of Lyndra Therapeutics, Inc., which aims to improve healthcare outcomes through oral, ultra-long acting sustained release medicines that change how people take medicines. Lyndra is developing a formulation targeted to maintain gastric residence for up to a month, so that medication can be taken weekly or even monthly, improving medication adherence for better healthcare outcomes.
Earlier this year, Dr. Hurter joined the Board of Directors of Synlogic, Inc., a public company (Nasdaq: SYBX) working at the intersection of biology and engineering, pioneering the application of synthetic biology to design living therapeutics programmed to treat disease in new ways.
Previously, Dr. Hurter was Senior Vice President of Pharmaceutical & Preclinical Sciences at Vertex Pharmaceuticals (Nasdaq: VRTX), an S&P 500 firm with $3 billion+ revenues. She was a key member of the leadership team that took Vertex from a virtual biotech with an $800 million market cap in 2004, to one of the top five and most admired biopharm companies, with four breakthrough drugs approved in 6 years, and a market cap of ~$45 billion in 2019. While at Vertex, Dr. Hurter led the team that designed and built a fully continuous drug product manufacturing line – the first of its kind in the world approved globally – that manufactures Vertex’s cystic fibrosis products. These products generated over $2 billion in revenues in 2018. While serving as interim head of Global Regulatory Affairs in 2013-2014, Dr. Hurter oversaw the submission of 4 new and supplementary drug approvals, including an NDA for Orkambi which generated $1.3 billion in revenue in 2017, and 3 Kalydeco label expansions which more than doubled the number of patients eligible for treatment with this medicine.
Prior to joining Vertex, Dr. Hurter was Director, Formulation Design and Characterization for Merck, where she was a key member of the early development team for the high-priority Merck DPPIV inhibitor approved in 2006 and subsequently marketed as Januvia for Type II diabetes. Today, the Januvia franchise is still Merck’s most profitable brand with sales of $6.1B (2017).
A respected thought leader in the pharmaceutical industry, Dr. Hurter was profiled in the best seller, “The Antidote” by Barry Werth (published in 2014), which chronicled the Vertex story. She is a frequent contributor to many scientific publications and speaks at pharmaceutical conferences throughout the world. She was named to the 2017 “Fiercest Women in Life Sciences” list by FiercePharma.
Dr. Hurter is an advocate for diversity and inclusion, and was the founder and executive sponsor of “IWILL,” a Vertex employee network devoted to the advancement of women leaders. Currently, Dr. Hurter serves as a member of the Board of Trustees for the Harvard Conservation Trust and is a past member of the Board of the IQ Consortium. She holds a PhD in Chemical Engineering from the Massachusetts Institute of Technology in Boston and a Master’s degree in Mechanical Engineering from West Virginia University in Morgantown, as well as a Bachelor’s degree in Chemical Engineering, cum laude, from the University of Natal in Durban, South Africa. Dr. Hurter completed the Harvard Business School Executive Education program, “Women on Boards: Succeeding as a Corporate Director.” An avid equestrian, she competes actively in show-jumping and lives in Harvard, Massachusetts with her husband and two children.